For surgical patients meeting criteria for the critical RBC administration threshold (CAT) due to an associated coagulation disorder, which hemostatic resuscitation strategy (goal-directed versus ratio-based) is superior?
Novel blood products are being developed based on innovative science (e.g., ex vivo manufactured RBC and platelets, and platelet and plasma derived hemostatic products). However, there is a significant lag in the development of appropriate tools and model systems, which poses a challenge when evaluating such products for regulatory approval.
2) Phase III efficacy trials of new and existing tuberculosis drugs to development very short course regimens (3-4 months).
3) Phase III efficacy trials of new and existing drugs for treatment of latent tuberculosis infection in contacts of... more »